Antimicrobial resistance (AMR) is projected to kill 39 million people and cost the global economy $100 trillion by 2050. No entirely new class of antibiotic has been discovered since the 1980s. The economics of antibiotic development are broken: a new class costs approximately $1.5 billion and 10-15 years to develop, with roughly 90% trial failure, yet generates only about $46M per year in average revenue. As a result, 18 major pharma firms have exited antibiotics since the 1990s, and 7 of the last 12 launchers went bankrupt or quit. Resistance is rising fastest exactly where the pipeline is emptiest.

DrugBoost takes the "resistance breaker" approach: rather than discovering new antibiotic classes, it pairs failing antibiotics with approved booster compounds to lower the effective bactericidal concentration and block resistance pathways. Its lead asset, OLIPEN® (AMX-CA-CN: amoxicillin 500 mg + clavulanate 62.5 mg + 1,8-cineole 100 mg), forms a stable molecular complex that simultaneously targets beta-lactamases (ESBL and carbapenemase), efflux pumps, persistence proteins, and biofilm, making it difficult for bacteria to evade. In vitro, OLIPEN® achieves over 800x lower bactericidal concentration vs amoxicillin alone against K. pneumoniae, and eliminates persister subpopulations within 30 minutes. A pilot clinical study cleared 21 of 23 multidrug-resistant UTI patients after other antibiotics had failed. The platform is designed to extend to additional antibiotic and booster pairs, with preliminary in vitro, in silico, and in vivo data supporting a broader pipeline.